SA523451347B1 - Psd-95 مثبطات واستخداماتها - Google Patents
Psd-95 مثبطات واستخداماتهاInfo
- Publication number
- SA523451347B1 SA523451347B1 SA523451347A SA523451347A SA523451347B1 SA 523451347 B1 SA523451347 B1 SA 523451347B1 SA 523451347 A SA523451347 A SA 523451347A SA 523451347 A SA523451347 A SA 523451347A SA 523451347 B1 SA523451347 B1 SA 523451347B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- psd
- inhibitors
- protein
- binding
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21173587 | 2021-05-12 | ||
| PCT/EP2022/062893 WO2022238530A1 (en) | 2021-05-12 | 2022-05-12 | Psd-95 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA523451347B1 true SA523451347B1 (ar) | 2024-08-27 |
Family
ID=75914418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA523451347A SA523451347B1 (ar) | 2021-05-12 | 2023-10-30 | Psd-95 مثبطات واستخداماتها |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4706670A1 (en) * | 2023-04-26 | 2026-03-11 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Psd-95 domain inhibitor, and preparation method therefor and use thereof |
| WO2025009503A1 (ja) * | 2023-07-03 | 2025-01-09 | メスキュージェナシス株式会社 | 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 |
| WO2025051130A1 (zh) * | 2023-09-07 | 2025-03-13 | 湖南中晟全肽生物科技股份有限公司 | 作为神经保护剂的药用化合物及其应用 |
| CN117164725B (zh) * | 2023-09-07 | 2024-05-10 | 湖南中晟全肽生物科技股份有限公司 | 一种突触后密度蛋白-95抑制剂多肽 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2320927T3 (pl) | 2008-07-09 | 2016-02-29 | Univ Copenhagen | Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD |
| KR102046830B1 (ko) | 2011-05-13 | 2019-11-20 | 코벤하븐스 유니버시테트 | 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제 |
| WO2020083905A1 (en) * | 2018-10-22 | 2020-04-30 | University Of Copenhagen | Inhibitors of pick1 and uses thereof |
-
2022
- 2022-05-11 TW TW111117679A patent/TW202306965A/zh unknown
- 2022-05-12 CA CA3218073A patent/CA3218073A1/en active Pending
- 2022-05-12 BR BR112023021410A patent/BR112023021410A2/pt unknown
- 2022-05-12 PL PL22728608.5T patent/PL4337673T3/pl unknown
- 2022-05-12 KR KR1020237037930A patent/KR20240007140A/ko active Pending
- 2022-05-12 JP JP2023569757A patent/JP2024520234A/ja active Pending
- 2022-05-12 IL IL307244A patent/IL307244A/en unknown
- 2022-05-12 WO PCT/EP2022/062893 patent/WO2022238530A1/en not_active Ceased
- 2022-05-12 ES ES22728608T patent/ES3040762T3/es active Active
- 2022-05-12 AU AU2022274309A patent/AU2022274309A1/en not_active Abandoned
- 2022-05-12 EP EP22728608.5A patent/EP4337673B1/en active Active
- 2022-05-12 MX MX2023013313A patent/MX2023013313A/es unknown
- 2022-05-12 US US18/559,157 patent/US20240245793A1/en active Pending
- 2022-05-12 CN CN202280033562.9A patent/CN117295755A/zh active Pending
-
2023
- 2023-09-12 ZA ZA2023/08712A patent/ZA202308712B/en unknown
- 2023-10-30 SA SA523451347A patent/SA523451347B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240007140A (ko) | 2024-01-16 |
| IL307244A (en) | 2023-11-01 |
| CA3218073A1 (en) | 2022-11-17 |
| US20240245793A1 (en) | 2024-07-25 |
| TW202306965A (zh) | 2023-02-16 |
| BR112023021410A2 (pt) | 2023-12-19 |
| AU2022274309A1 (en) | 2023-09-28 |
| MX2023013313A (es) | 2023-12-04 |
| CN117295755A (zh) | 2023-12-26 |
| EP4337673B1 (en) | 2025-07-09 |
| AU2022274309A9 (en) | 2024-01-25 |
| EP4337673A1 (en) | 2024-03-20 |
| ZA202308712B (en) | 2025-02-26 |
| WO2022238530A1 (en) | 2022-11-17 |
| PL4337673T3 (pl) | 2026-01-05 |
| ES3040762T3 (en) | 2025-11-04 |
| JP2024520234A (ja) | 2024-05-23 |
| EP4337673C0 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308712B (en) | Psd-95 inhibitors and uses thereof | |
| MX2025011950A (es) | Inhibidores macrociclicos de ras | |
| MX2022005360A (es) | Inhibidores de ras. | |
| MX2022005359A (es) | Inhibidores de ras. | |
| MX2022005357A (es) | Inhibidores de ras. | |
| SA521422459B1 (ar) | مثبطات غير قابلة للانعكاس لتفاعل المينين - mll | |
| ATE489088T1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
| GEP20247710B (en) | Small molecule inhibitors of kras g12c mutant | |
| MX2023007497A (es) | Nuevos derivados de quinazolina como inhibidores de sos1 y uso de los mismos. | |
| EP4506001A3 (en) | SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS | |
| CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
| MX2020007898A (es) | Moduladores de cinasa de proteina asociada con rho. | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| EA201000915A1 (ru) | Ингибиторы пролилгидроксилазы | |
| CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
| CY1117986T1 (el) | Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου | |
| DE602004019548D1 (de) | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) | |
| EA202091803A1 (ru) | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| BRPI0815048A2 (pt) | derivado de fenóxi-pirrolidinas e uso e composições do mesmo | |
| EA200600588A1 (ru) | Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз | |
| EA201991511A1 (ru) | Кристаллическая структура гремлин-1 и ингибирующее антитело | |
| MX2016006966A (es) | Derivados de acidos grasos de inhibidores dimericos de la proteina 95 de la densidad post-sinaptica (psd-95). | |
| EA202192420A1 (ru) | Применение онколитических вирусов для лечения рака |